Tuesday, February 28, 2023

Financial News Conference on the Full Year 2022 Results

Bayer: Significant Growth in Sales and Earnings

  • Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros
  • EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science
  • Pharmaceuticals increases sales and earnings
  • Consumer Health maintains dynamic growth
  • Core earnings per share advance 22.0 percent to 7.94 euros
  • Net income of 4.150 billion euros
  • Free cash flow increases to 3.111 billion euros, net financial debt down to 31.809 billion euros
  • Dividend of 2.40 euros per share proposed, up 20 percent
  • New products post significant growth / Encouraging developments in the research pipeline
  • Major progress made toward achieving long-term sustainability targets
  • Outlook for 2023: Increase in sales (Fx & portfolio adj.); EBITDA before special items and core earnings per share below prior year as inflation remains high

MORE

Recording (partly dubbed into English):

Audio:

 

(MP3 download, 113.97 MB)


Statement in written form

 

Recording (partly dubbed into English):

Audio:

(MP3 download, 52.17 MB)

Recording (partly dubbed into English):

Audio:

(MP3 download, 59.09 MB)

Stay tuned and follow us:

 twitter40

   Twitter

 

LinkedIn

   LinkedIn